NCT01980615View on ClinicalTrials.gov

Phase I Study Evaluating the Safety and Pharmacokinetics of Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (BGF MDI) in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Healthy Volunteers
Interventions
DRUG

Inhaled BGF (PT010) Dose 1

DRUG

Inhaled BGF (PT010) Dose 2

DRUG

Inhaled BGF (PT010) Dose 3

DRUG

Inhaled GFF (PT003)

DRUG

Inhaled Symbicort Dose 1

DRUG

Inhaled Symbicort Dose 2

Trial Locations (1)

Unknown

Pearl Therapeutics Study Site, Baltimore

Sponsors
All Listed Sponsors
lead

Pearl Therapeutics, Inc.

INDUSTRY